Jacobs Engineering Group Inc. announced today it was awarded a contract to expand the Novartis Pharma S.A.S. Biotechnology Center in Huningue, France.
Under the terms of the agreement, Jacobs is providing engineering, procurement and construction management (EPCM) services to increase the sites production capacity by 70 percent and create a second line of purification that allows for multiple drugs to be manufactured simultaneously.
Already one of the worlds largest production facilities for monoclonal antibodies from mammalian cells, the expansion project adds cell culture bioreactors to the site.
Jacobs services are being led from its operations in Milan, Italy.
In making the announcement, Jacobs Senior Vice President Life Sciences Robert Norfleet stated, We look forward to partnering with Novartis on the expansion of its Huningue site. Were proud to have this opportunity to draw on our extensive global EPCM expertise for a project that can help Novartis improve the lives of people who depend on its treatments.
Under the terms of the agreement, Jacobs is providing engineering, procurement and construction management (EPCM) services to increase the sites production capacity by 70 percent and create a second line of purification that allows for multiple drugs to be manufactured simultaneously.
Already one of the worlds largest production facilities for monoclonal antibodies from mammalian cells, the expansion project adds cell culture bioreactors to the site.
Jacobs services are being led from its operations in Milan, Italy.
In making the announcement, Jacobs Senior Vice President Life Sciences Robert Norfleet stated, We look forward to partnering with Novartis on the expansion of its Huningue site. Were proud to have this opportunity to draw on our extensive global EPCM expertise for a project that can help Novartis improve the lives of people who depend on its treatments.